top of page

Featured Product:
Darunavir/ritonavir (400/50 mg) fixed-dose combination

Latest DRV/r (400/50 mg) Resources

Darunavir (DRV) is a best in class protease inhibitor commonly used in high-income markets, and has recently been prequalified by the WHO as a fixed-dose-combination with ritonavir (RTV) at a price of US $17.50/pack (EXW) for use in second-line in low- and middle-income countries. CHAI is pleased to share a set of resources to support national decision-making and implementation of this optimal product. Please contact with any questions about the resources listed here.

Product Adoption

Implementation Resources

Tools and resources to support management and coordination of product phase-in as rollout activities take place at the facility level. 

Additional Resources Coming Soon!
Implementation Resources

Pricing, Quantification, and Monitoring Resources

Tools, guidance, and resources to support countries with budgeting, conducting quantification and supply planning, and monitoring uptake.

Additional Resources Coming Soon!
Pricing, Quantificatin, Monitoring
bottom of page